Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen?
We have ourselves a horse race to watch in KRAS G12C, but it’s going to be awfully hard to call at this very early stage of the competition.
Mirati — $MRTX led by CEO Chuck Baum — came through with an encouraging set of responses to review for MRTX849 — particularly among a group of 6 evaluable patients suffering from non-small cell lung cancer who had received a dose of 600 mg twice daily, which is the high dose they plan to take forward as most likely to get a response with the least amount of potential harm to the patient.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.